本文選題：hMLH1　切入點(diǎn)：hMSH2　出處：《河南科技大學(xué)》2011年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:檢測(cè)下咽癌及切緣和正常喉咽組織中hMLH1、hMSH2的表達(dá)狀況,揭示其與下咽癌發(fā)生發(fā)展預(yù)后的關(guān)系,以期為下咽癌的早期診斷、判斷預(yù)后和基因治療及其預(yù)防提供理論依據(jù),并探討下咽癌手術(shù)的安全切緣。 方法:本研究采用免疫組化SP法,從2008-2010年手術(shù)治療的不同分期分級(jí)的下咽癌患者中隨機(jī)選取50例,每例取癌組織、表面癌旁3mm,5mm,10mm石蠟標(biāo)本切片,并取20例正常喉組織做對(duì)照,檢測(cè)下咽癌及切緣和正常咽組織中hMLH1和hMSH2的表達(dá)狀況,由此探討其與下咽癌發(fā)生發(fā)展和預(yù)后的關(guān)系,以及判定下咽癌手術(shù)的安全切緣范圍。 結(jié)果: 1.hMLH1與hMSH2蛋白陽(yáng)性表達(dá)主要位于細(xì)胞核,為棕褐色或黃色,一少部分位于細(xì)胞漿即核漿型,著色較淺且分布均勻。 2.在下咽癌和正常喉組織中hMLH1蛋白的陽(yáng)性率分別為54%和80%,兩組間表達(dá)差異具有統(tǒng)計(jì)學(xué)意義(P0.05);hMSH2蛋白的陽(yáng)性率分別為56%和85%,兩組間表達(dá)差異差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。 3.hMLH1與hMSH2蛋白的表達(dá)和下咽癌患者性別、年齡和臨床分期無(wú)明顯相關(guān)(P 0.05)。 4.hMLH1與hMSH2蛋白的表達(dá)與下咽癌的分化程度和淋巴結(jié)轉(zhuǎn)移有明顯相關(guān)(P0.05)。 5.在下咽癌組織中hMLH1與hMSH2蛋白的表達(dá)呈正相關(guān),r=0.713(P0.05)。 6. hMLH1與hMSH2蛋白的陽(yáng)性表達(dá)按癌組織、癌旁3mm、5mm、10mm和正常喉組織的順序依次遞增,越靠近正常組織,陽(yáng)性表達(dá)越高。差異具有顯著性(P0.05)。 結(jié)論:1.下咽癌細(xì)胞中存在hMLH1與hMSH2基因蛋白的表達(dá)下調(diào),hMLH1與hMSH2基因蛋白的缺失,可能參與了下咽癌早期的發(fā)生過程。 2.hMLH1與hMSH2基因蛋白的表達(dá)與下咽癌患者性別、年齡、臨床分期無(wú)相關(guān)性。 3.hMLH1與hMSH2基因蛋白的表達(dá)與下咽癌的分化程度、淋巴結(jié)轉(zhuǎn)移相關(guān)。 4.下咽癌組織中hMLH1、hMSH2蛋白的表達(dá)呈正相關(guān),hMLH1與hMSH2可能一起參與了下咽癌的發(fā)生、發(fā)展、侵襲及轉(zhuǎn)移的過程。 5.hMLH1與hMSH2有可能成為下咽癌預(yù)警的標(biāo)記物。 6.在下咽癌中檢測(cè)hMLH1與hMSH2基因蛋白,將可為研究下咽癌的發(fā)生發(fā)展及其基因治療提供理論依據(jù)。 7.下咽癌手術(shù)可以選擇距腫瘤10mm作為安全切緣參考標(biāo)準(zhǔn)。
[Abstract]:Objective: to detect the expression of hMLH1hMSH2 in hypopharyngeal carcinoma and its incisal margin and normal larynx tissue, and to reveal the relationship between hMLH1hMSH2 and the prognosis of hypopharyngeal carcinoma, so as to provide theoretical basis for early diagnosis, judgement of prognosis, gene therapy and prevention of hypopharyngeal carcinoma. And to explore the safe margin of hypopharyngeal carcinoma surgery. Methods: in this study, 50 patients with hypopharyngeal carcinoma were randomly selected from 50 patients with hypopharyngeal carcinoma in different stages and grades treated by operation from 2008 to 2010 by immunohistochemical SP method. Each case was taken from the cancer tissue, and the paraffin sections of 3 mm to 5 mm or 10 mm adjacent to the surface carcinoma were taken, and 20 cases of normal laryngeal tissue were taken as control. To detect the expression of hMLH1 and hMSH2 in hypopharyngeal carcinoma and its incisal margin and normal pharyngeal tissue, and to explore the relationship between the expression of hMLH1 and hMSH2 and the occurrence, development and prognosis of hypopharyngeal carcinoma, and to determine the safe margin of surgery for hypopharyngeal carcinoma. Results: 1. The positive expression of hMLH1 and hMSH2 protein was mainly located in the nucleus, which was brown or yellow, and a few in the cytoplasm, the staining was light and evenly distributed. 2. 2. The positive rates of hMLH1 protein in hypopharyngeal carcinoma and normal larynx were 54% and 80, respectively. The positive rates of hMLH1 protein were 56% and 85 in hypopharyngeal carcinoma and normal larynx, respectively. The difference between the two groups was statistically significant (P 0.05). 3. There was no significant correlation between hMLH1 expression and hMSH2 protein expression, sex, age and clinical stage of patients with hypopharyngeal carcinoma (P 0.05). 4. The expression of hMLH1 and hMSH2 protein was significantly correlated with the degree of differentiation and lymph node metastasis of hypopharyngeal carcinoma. 5. There was a positive correlation between the expression of hMLH1 and hMSH2 protein in hypopharyngeal carcinoma tissues. 6. The positive expression of hMLH1 and hMSH2 protein increased in the order of cancer tissue, adjacent 3 mm ~ 5 mm ~ 10 mm and normal laryngeal tissue. The closer the tissue was to the normal tissue, the higher the positive expression was, and the difference was significant (P 0.05). Conclusion the expression of hMLH1 and hMSH2 gene protein down-regulated the deletion of hMLH1 and hMSH2 gene protein in hypopharyngeal carcinoma cells, which may be involved in the early development of hypopharyngeal carcinoma. 2. The expression of hMLH1 and hMSH2 gene protein had no correlation with sex, age and clinical stage of patients with hypopharyngeal carcinoma. 3. The expression of hMLH1 and hMSH2 gene protein was correlated with the differentiation of hypopharyngeal carcinoma and lymph node metastasis. 4. The expression of hMLH1hMSH2 protein was positively correlated with the expression of hMLH1hMSH2 protein in hypopharyngeal carcinoma tissues. HMLH1 and hMSH2 may be involved in the process of occurrence, development, invasion and metastasis of hypopharyngeal carcinoma. 5. HMLH1 and hMSH2 may be markers for early warning of hypopharyngeal cancer. 6. Detection of hMLH1 and hMSH2 gene proteins in hypopharyngeal carcinoma may provide theoretical basis for the study of the occurrence and development of hypopharyngeal carcinoma and its gene therapy. 7. For hypopharyngeal carcinoma surgery, 10 mm away from the tumor can be selected as the reference standard for the safe margin of resection.
【學(xué)位授予單位】：河南科技大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2011
【分類號(hào)】：R739.64

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 游龍貴,孫煒,孫彥,張克輝,張小安,蘭玉清;喉癌手術(shù)切緣Bcl-2、Bax及Bak蛋白的表達(dá)[J];青島大學(xué)醫(yī)學(xué)院學(xué)報(bào);2005年01期

2 谷建琦;張英懷;董青;賈志宇;;hMLH1、hMSH2蛋白在口腔鱗狀細(xì)胞癌中的表達(dá)及意義[J];北京口腔醫(yī)學(xué);2007年02期

3 周琪,閻曉初,辛榕,段光杰,章容,柳鳳軒;大腸腺瘤及其癌變錯(cuò)配修復(fù)基因hMLH1和hMSH2表達(dá)與細(xì)胞增殖的關(guān)系[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2004年07期

4 趙堅(jiān)強(qiáng);;下咽癌的手術(shù)治療回顧與展望[J];臨床醫(yī)學(xué);2006年07期

5 郭成;車向明;劉青光;;hMSH2,hMLH1的表達(dá)與胃癌臨床病理及預(yù)后的關(guān)系[J];廣東醫(yī)學(xué);2008年01期

6 楊勝利,譚家駒,楊光;DNA損傷修復(fù)基因多態(tài)性與食管癌的研究進(jìn)展[J];國(guó)外醫(yī)學(xué).外科學(xué)分冊(cè);2005年03期

7 李佩玲,劉梅梅;錯(cuò)配修復(fù)基因hMSH2研究的新進(jìn)展[J];國(guó)外醫(yī)學(xué).遺傳學(xué)分冊(cè);2002年04期

8 范凱;馬堅(jiān)妹;王朝暉;王彥;劉敏;呂申;許國(guó)旺;;胃癌中hMSH2、PTEN和PCNA表達(dá)的相關(guān)性及意義[J];解剖學(xué)雜志;2006年01期

9 李為民,郭睿,郭志祥;喉癌手術(shù)切緣的組織病理學(xué)研究[J];臨床耳鼻咽喉科雜志;1998年11期

10 孫越峰;喉癌手術(shù)切緣的研究進(jìn)展[J];臨床耳鼻咽喉科雜志;2001年09期

，

本文編號(hào)：1572203